This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Fibrocell Science

As a stock, Genta stopped mattering long ago after multiple Genasense clinical trial failures and almost as many FDA rejections. Only Warrell believed in the drug, keeping Genta afloat on the bulletin boards by selling billions (literally) of shares to fund his Genasense development efforts. This week, even Warrell had to throw in the towel.

Goodbye, Genasense.

@Superduty03 tweets, "Adam, will you be posting a breakdown of your top 5 or 10 companies that interest you at ASCO?"

I'll be in Chicago next Friday for the American Society of Clinical Oncology annual meeting, which kicks off in earnest on Saturday, June 4 and runs through Tuesday, June 7.

As I did last year, I will be live-blogging from ASCO on Saturday, Sunday and Monday, hoping to provide you with real-time coverage of cancer drug data presentations and the investor buzz from the ASCO hallways.

I've been calling this year an "incremental" ASCO meeting mainly because big, stock-moving data presentations are in short supply. In terms of companies that interest me at ASCO this year, I'm eager to check out the data from YM BioSciences (YMI), Exelixis (EXEL) and Neoprobe (NEOP). Incyte (INCY) could be a mover after the presentation of not-yet-seen phase III data on its myelofibrosis drug. The evolving prostate cancer treatment landscape is a big story for oncologists and investors, which for the latter means volatility in Dendreon, Johnson & Johnson (JNJ), Medivation (MDVN) and Exelixis.

I still haven't nailed down my schedule for ASCO, it's on the to-do list for this weekend, so expect a more detailed breakdown of my ASCO plans next week before I get on the plane for Chicago.

George H. gripes on Avanir Pharmaceuticals (AVNR) and my story about the congressional inquiry into the pricing of its new drug Nuedexta.

George writes, "I have requested, as have many, an investigation into the senators regarding this Avanir article and also the whole manipulation of this stock!"

Good luck with that. Don't forget your tin-foil hat.

Michael B. writes, "I appreciate your articles, although I do not agree with some points, they are truthful and sometimes people don't want to hear the truth. But I do appreciate your efforts. I wanted to get your thoughts on MannKind(MNKD). This company appears to be three years out from any type of revenues, but supports a $500M+ market cap at this point? Where do you see the company in 30 days, 60 days, 1 year and what do you think could possible behind the rationale that this company is worth as much as Wall Street is currently valuing at?"

My old friend and former colleague Herb Greenberg (he's on CNBC now) once gave me a bit of very good advice. He told me that stocks lie all the time. By stocks, he meant stock prices, which go up and down for all kinds of reasons, many of them having nothing to do with fundamentals or the long-term prospects of the companies they represent.

I remember Greenberg's words when I see MannKind trading above $4 a share. Stocks lie.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
4 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
DSCI $7.23 1.10%
EXEL $6.09 6.30%
MNKD $4.16 -3.00%
AAPL $118.18 -2.60%
FB $94.06 0.05%

Markets

Chart of I:DJI
DOW 17,579.96 -109.90 -0.62%
S&P 500 2,094.44 -9.40 -0.45%
NASDAQ 5,107.34 -20.9410 -0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs